By Alan Mozes HealthDay Reporter
TUESDAY, July 20, 2021 (HealthDay Information)
For sufferers with a historical past of hypertension or coronary heart illness, the reply seems to be sure. At the very least that is the conclusion of a brand new research that enlisted roughly 10,500 sufferers throughout 104 U.S. hospitals between January and September of 2020.
All had been admitted with a severe bout of COVID-19. Previous to hospitalization, 42% had been taking statins to rein in excessive ldl cholesterol, with 7% taking statins alone and 35% taking each statins and blood stress drugs.
“[But] we discovered that sufferers taking statin drugs previous to getting hospitalized resulting from COVID-19 had a 41% decrease danger of dying throughout that hospitalization, even after adjusting for different elements like age, gender, different medical issues, and what sort of medical insurance coverage that they had,” mentioned research creator Dr. Lori Daniels.
After analyzing knowledge amassed by the American Coronary heart Affiliation, the group additionally concluded that statin use was equally linked to a 25% decrease danger for creating a “extreme final result” on account of COVID-19 an infection.
Why? Statins might need this impact by “stabilizing the underlying coronary heart situations for which they’re prescribed, making sufferers extra more likely to recuperate from COVID-19,” mentioned Daniels, director of the cardiovascular intensive care unit on the College of California, San Diego.
However not all sufferers on statins have superior coronary heart illness, Daniels’ group famous. Many comparatively wholesome sufferers additionally take them in proactively to stave off cardiovascular hassle.
Which begs the query, might statins additionally decrease demise amongst COVID sufferers who do not but have severe underlying coronary heart points? Daniels recommended the jury remains to be out on that query.
She famous that statins pack a probably useful anti-inflammatory punch. Her group discovered that statins drove demise danger down by 16% amongst sufferers with no prior historical past of coronary heart illness.
Nonetheless, Daniels cautioned that for coronary heart wholesome sufferers, the trial outcomes had been “not statistically important.” And “the current research can’t inform us whether or not giving sufferers statins, if they aren’t already on them, could be useful,” she confused.
“Nevertheless, in different settings in addition to COVID-19, corresponding to sufferers coming in with massive coronary heart assaults, research have proven that giving statins up entrance — early within the hospitalization to sufferers not already on them — improves outcomes,” Daniels mentioned, lowering the danger for future coronary heart assaults and demise.
“So, there may be precedent for statins making a distinction rapidly in hospitalized sufferers,” she famous.
Even so, Dr. Gregg Fonarow — director of the Ahmanson-UCLA Cardiomyopathy Middle — had a combined response to the findings.
He acknowledged that there has lengthy been curiosity in whether or not coronary heart medicine — together with hypertension drugs and statins– may provide COVID-19 sufferers a leg up with regards to reducing illness severity and fatalities.
“And quite a few observational research have recommended there have been associations between prior or continued used of those drugs and COVID-19 severity and scientific outcomes,” famous Fonarow, who wasn’t a part of the research.
However he confused that nailing down a possible profit could be very tough, given the big selection of things that may affect outcomes amongst COVID sufferers. And he identified that different trials involving coronary heart sufferers fighting COVID “have not discovered profit or harms” linked to both class of medicines.
Nonetheless, Fonarow famous that further trials are already underway. And “present pointers advocate continuation of those therapies,” he mentioned.
Daniels and her colleagues printed their findings July 15 within the journal PLOS ONE.
The American Coronary heart Affiliation has extra on COVID and coronary heart sufferers.
SOURCES: Lori Daniels, MD, director, cardiovascular intensive care unit, College of California, San Diego; Gregg Fonarow, MD, director, Ahmanson-UCLA Cardiomyopathy Middle, Los Angeles; PLOS ONE, July 15, 2021
Copyright © 2021 HealthDay. All rights reserved.